Study A): At this point, we know little about the most effective treatment schedule with PDCs. For this reason, and based on published literature, we will first test the systemic tolerance of the animals to the drugs in the PDCs by injecting groups of non-tumor bearing mice intraperitoneally with 1, 7.5 or 15 mg/Kg of one Chlorambucil and Combretastatin 4A containing PDC every third days for 3 weeks. Animals will be monitored for systemic morbidity and survival. On the basis of these results, an initial treatment schedule will be selected to compare two concentrations for each of the two PDCs. Animals showing initial signs of CLL will be treated and followed for survival and development of CLL symptoms for at least and additional 70 days.